{"id":16618,"date":"2021-03-24T13:59:44","date_gmt":"2021-03-24T12:59:44","guid":{"rendered":"https:\/\/www.izb-online.de\/leukocare-und-formycon-kooperieren-bei-der-entwicklung-von-hochwertigen-biopharmazeutika\/"},"modified":"2021-03-24T14:27:28","modified_gmt":"2021-03-24T13:27:28","slug":"leukocare-and-formycon-cooperate-in-the-development-of-high-quality-biopharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/leukocare-and-formycon-cooperate-in-the-development-of-high-quality-biopharmaceuticals\/","title":{"rendered":"Leukocare and Formycon cooperate in the development of high-quality biopharmaceuticals"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Leukocare and Formycon cooperate in the development of high-quality biopharmaceuticals<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Companies combine leading development expertise in high-quality biopharmaceuticals with profound knowhow in biopharmaceutical formulation development[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]March 2021[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”16613″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Adobe Stock[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Illustration of antibodies[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cWe are very proud of this partnership with Formycon, a world-leading developer of high-quality biosimilars and biopharmaceuticals. This collaboration is a perfect fit for both companies to drive the development of high-quality products.\u201d<\/h6>\n

Michael Scholl
\nChief Executive Officer bei Leukocare<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Leukocare AG and Formycon AG today announced a collaboration in the area of high-quality biopharmaceuticals. Under the terms of this agreement, Leukocare will apply its formulation development technologies combining state-of-the art protein analytics, bioinformatics and artificial intelligence to develop stable formulations potentially for several candidates in Formycon\u00b4s product pipeline. The first project has been started and covers the formulation development for a biosimilar of a blockbuster therapeutic antibody.<\/p>\n

By applying Leukocare\u2019s formulation and bioinformatics expertise to Formycon\u2019s comprehensive development knowhow, the partners want to achieve superior stability profiles overall leading to additional value propositions for development projects.<\/p>\n

Michael Scholl, Chief Executive Officer at Leukocare, commented, \u201cWe are very proud of this partnership with Formycon, a world-leading developer of high-quality biosimilars and biopharmaceuticals. This collaboration is a perfect fit for both companies to drive the development of high-quality products.\u201d<\/p>\n

Andreas Seidl, Chief Operating Officer of Leukocare, added, \u201cOur algorithm-based formulation development expertise will allow Formycon to make use of a large formulation design space, thereby gaining manifold options for freedom to operate in a competitive environment. This will strongly support Formycon in providing high-quality medicines to as many patients as possible.\u201d<\/p>\n

Stefan Glombitza, Chief Operating Officer at Formycon, stated, \u201cSuitable Drug Product formulations are an essential success factor in the development of biopharmaceutical drugs and are getting increasingly important in the competitive IP landscape. We are convinced that Leukocare’s technology platform can successfully complement our development expertise and look very much forward to our collaboration.\u201d[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n